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The retinal vessels have two barriers: the retinal pigment epithelium and the retinal vascular endothelium. Each barrier exhibits
increased permeability under various pathological conditions. This condition is referred to as blood retinal barrier (BRB) break-
down. Clinically, the most frequently encountered condition causing BRB breakdown is diabetic retinopathy. In recent studies,
inﬂammation has been linked to BRB breakdown and vascular leakage in diabetic retinopathy. Biological support for the role of
inﬂammationinearlydiabetesistheadhesionofleukocytestotheretinalvasculature(leukostasis)observedindiabeticretinopathy.
PPARγ is a member of a ligand-activated nuclear receptor superfamily and plays a critical role in a variety of biological processes,
including adipogenesis, glucose metabolism, angiogenesis, and inﬂammation. There is now strong experimental evidence to sup-
portthetheorythatPPARγ inhibitsdiabetes-inducedretinalleukostasisandleakage,playinganimportantroleinthepathogenesis
of diabetic retinopathy. Therapeutic targeting of PPARγ may be beneﬁcial to diabetic retinopathy.
Copyright © 2008 Yasuo Yanagi.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. BLOOD RETINAL BARRIER (BRB) BREAKDOWN
IN DIABETIC RETINOPATHY
The retinal vessels have a barrier consisting of the tight junc-
tion of the retinal pigment epithelium and the retinal vas-
cular endothelium. Each barrier exhibits increased perme-
ability under various pathological conditions. This condi-
tion is referred to as blood retinal barrier (BRB) break-
down. Clinically, the most frequently encountered condi-
tion that induces vascular permeability is diabetic retinopa-
thy [1]. BRB breakdown causes retinal edema. Clinically,
the retinal edema often aﬀects macula, the highly sensi-
tive area of the central retina, and often severely aﬀects vi-
sion (Figure 1). The frequency of diabetic macular edema
ranges from 2% to 13.3% of all diabetic patients, and 6.7%
to 62% of insulin-dependent diabetic patients, and its inci-
d e n c ei s1 . 3 %t o5 . 1 %o v e raf o u r - y e a ro b s e r v a t i o np e r i o d
[2]. Due to the enhanced retinal vascular permeability, en-
dothelial cell damage and capillary nonperfusion are aggra-
vated. Much eﬀort has been directed toward establishing ef-
fectivetreatments,andrecentclinicalstudieshavefoundthat
laser photocoagulation, pars plana vitrectomy, and antivas-
cular endothelial growth factor (VEGF) therapy might be ef-
fective in ameliorating macular edema [3–6], but the treat-
ment eﬃcacy is limited and the results of the preliminary
clinical investigation will have to be conﬁrmed by further
studies.
2. THEROLEOFINFLAMMATIONINBRBBREAKDOWN
In recent studies, inﬂammation has been linked to vascu-
lar leakage in diabetic retinopathy [7]. Biological support
for the role of inﬂammation in early diabetes is the ad-
hesion of leukocytes to the retinal vasculature (leukostasis)
observed in both experimental diabetic retinopathy in rats
and in human diabetic retinopathy [8, 9]. Increased adhe-
sion of leukocytes to the retinal vasculature is considered to
promote vascular leakage. Thus, leukostasis is considered to
be a critical event in the pathogenesis of diabetic retinopa-
thy. Clinical investigations have demonstrated that the vit-
reous level of VEGF protein is higher in patients with di-
abetic macular edema than in patients with other condi-
tions [10]. Ample evidence suggests that the adhesion of
leukocytes to the retinal capillaries is controlled by vas-
cular endothelial growth factor (VEGF), and focal adhe-
sion molecules such as the intercellular adhesion molecule2 PPAR Research
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Figure 1: Macular edema in diabetic retinopathy. (a) Macular
edema in diabetic retinopathy. (b) Increased vascular permeability
is observed by ﬂuorescin angiography. Note the leakage of the ﬂuo-
rescent dye showing the blood retinal barrier breakdown. Although
theretinopathyismild,thispatienthasavisualacuityof20/200due
to severe macular edema.
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Figure 2: Schematic representation of the molecular mechanism
of macular edema. VEGF drives the expression of ICAM-1 in the
retinal vessels, which subsequently makes CD18+ leukocytes adher-
ent to the retinal vessels. Adhesion of leukocytes to the retinal ves-
sels leads to increased vascular leakage, subsequent endothelial cell
damage, and capillary nonperfusion.
1 (ICAM1) [11]. It is a commonly accepted molecular mech-
anism of leukocyte adhesion that VEGF drives the upreg-
ulation of the ICAM-1 molecule in the retinal endothelial
cells [12, 13], and that this upregulated ICAM-1, together
with upregulated leukocyte integrin CD18, triggers adhesion
of leukocytes to the retinal vessels [14]. Indeed, CD18(−/−)
and ICAM-1 (−/−) mice demonstrate signiﬁcantly fewer ad-
herent leukocytes in the retinal vasculature after the induc-
tion of diabetes with streptozotocin (STZ) [15]. It is, how-
ever, not only VEGF but also several other molecules that
are involved in the expression of ICAM-1. NF-κBm o l e c u l e s ,
activated by inﬂammation, also drive ICAM-1 expression
[16]. Furthermore, blockage of the bioactivity of VEGF or
ICAM-1 or inhibition of inﬂammatory pathways leads to
decreased retinal leukocyte adhesion and reduced vascular
leakage [17]. Thus, it is generally assumed that the upreg-
ulation of the adhesion molecule, triggered by VEGF and
other inﬂammatory stimuli, is important in the leukostasis
(Figure 2).
3. PPARγ AND INFLAMMATION
PPARγ is a member of a ligand-activated nuclear receptor
superfamily and plays a critical role in a variety of biolog-
ical processes, including adipogenesis, glucose metabolism,
angiogenesis, and inﬂammation [18]. Synthetic ligands of
PPARγ, that is, thiazolidine derivatives such as rosiglita-
zone and pioglitazone, are used as oral antihyperglycemic
agents for the therapy of non-insulin-dependent diabetes
mellitus. In addition, recent studies have shown that PPARγ
ligands modulate the production of inﬂammatory media-
tors [19]. Actually, it has been reported that PPARγ lig-
ands, such as rosiglitazone and pioglitazone, suppress in-
ﬂammatory diseases such as adjuvant-induced arthritis [19].
Importantly, some evidence suggests that PPARγ is in-
volved in the regulation of adhesion molecules. Previ-
ously, it has been demonstrated that PPARγ ligand sup-
pressed ICAM-1 expression in a murine model of intesti-
nal ischemia-reperfusion injury [20] and in human umbil-
ical vein endothelial cells in vitro [21]. Some of these anti-
inﬂammatory functions are mediated through the inhibition
of NF-κBa c t i v a t i o n( Figure 3). Considering the close link
between inﬂammation and diabetes, it is rational to con-
sider that PPARγ ligand therapy may also improve diabetic
retinopathy.
4. PPARγ IN BRB BREAKDOWN
We investigated the eﬀects of a synthetic PPARγ ligand,
rosiglitazone, on an experimental diabetic model [22]. Addi-
tionally, heterozygous PPARγ-deﬁcient (+/-) mice were used
in an experimental model to determine whether endoge-
nous PPARγ played a role [22]. Experimental diabetes was
induced by intraperitoneal injection of STZ. This model is
considered to destroy pancreatic beta cells completely [22]
Retinal leukostasis quantiﬁcation was performed by count-
ing the number of adherent leukocytes after ﬂuorescein-
isothiocyanide (FITC)-Concanavalin A lectin (Con A) per-
fusion. A retinal leakage assay was performed by evaluat-
ing the retinal concentration of FITC-dextran after the an-
imals were perfused. The results showed the PPARγ agonist,
rosiglitazone, inhibited both the retinal leukostasis and reti-
nal leakage observed in the experimental diabetic rats and
that the decreased expression of the endogenous PPARγ in
mice leads to the aggravation of retinal leukostasis and reti-
nal leakage in diabetic mice. Together, these ﬁndings sup-
port the theory that the PPARγ signaling pathway inhibits
diabetes-induced retinal leukostasis and leakage. In addition,
it was demonstrated that PPARγ ligand suppresses ICAM-1
expression, but not VEGF expression, raising the possibility
thatNF-κBmediatedICAM-1issuppressedbyPPARγ ligand
(Figure 4).Yasuo Yanagi 3
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Figure 3: PPARγ exerts anti-inﬂammatory eﬀects. Schematic representation showing molecular pathways mediating the anti-inﬂammatory
eﬀects of PPARγ ligands.
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Figure 4: Involvement of PPARγ ligand and its receptor system in
retinal leukostasis and vacular permeability. Schematic representa-
tion showing the role of PPARγ system in the retinal leukostasis and
vascular permeability in diabetic retinopathy.
These results provide strong evidence to support the the-
ory that PPARγ activity plays an important role in the patho-
genesis of diabetic retinopathy and introduce the novel pos-
sibility that the therapeutic targeting of PPARγ may be ben-
eﬁcial to diabetic retinopathy.
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